Wearable Medical Devices Patents: Top Companies & Trends 2026
- Concentrated at the top. The five leading assignees hold 65.8% of all 798 records in scope, and the ranked ten hold 93.7% — a small group of research institutes and device makers controls most of the filed claim space.
- Filing has cooled from its 2019 peak. Volume peaked at 136 records in 2019; from 2021 to 2024, the last fully comparable years, filings fell 34%, from 89 to 59.
- Electrotherapy and informatics dominate the claims. A61N (electrotherapy & radiation therapy) appears in 36.7% of records and G16H (healthcare informatics) in 26.8%, while commerce-adjacent classes like G06Q sit far behind at 5.8%.
Filing growth compares 2021 (89 records) with 2024 (59) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 798 records in scope (CR5), not by the ranked leaders only.
What the wearable medical device patent record shows
Wearable medical device filings sit at the intersection of sensing hardware, body-worn form factors and clinical measurement — the search scope here pulls records that combine a wearable or body-worn device claim with a clinical, diagnostic or device-interface element, rather than general consumer fitness wearables. Across 798 records published between 2015 and 2026, the field shows a pattern common to instrumentation-heavy medtech: a handful of research institutions and device incumbents hold the earliest and broadest claims, while a long tail of single- or few-filing entrants files around specific implementations.
Publication lags filing by roughly 18 months, so the 2025 and 2026 figures in any trend line understate real filing activity for those years; treat 2024 as the most recent year that can be read as complete.
Filing trend and technology composition
Two views of the same 798 records: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017–2026
Filings rose to a peak of 136 records in 2019, then eased back; the comparable 2021-to-2024 window shows a 34% decline, from 89 to 59 records. The final one or two years on the chart are still filling in as later-filed applications publish.
IPC subclass composition
A61N (electrotherapy & radiation therapy) and G16H (healthcare informatics) lead at 36.7% and 26.8% of the 798 records respectively, with A61B (diagnosis & surgery) close behind at 25.1%. Genetic and enzymatic measurement classes (C12N, C12Q) each clear 12%, showing a real overlap between wearable sensing and molecular diagnostics rather than pure electronics. Records can carry more than one class, so these shares add to well over 100%.
Shares are the percentage of the 798 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Wearable Medical Devices Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about wearable medical devices patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA representative filing and the most-cited prior art
US20200009321A1 — Wearable medical device for monitoring intravenous injection
A wearable medical device comprising an annular housing configured to attach to a wrist of a patient. The device includes a receptacle for a portion of an intravenous delivery tube and a flow regulator in contact with that tube, configured to modify a geometric characteristic of the tube, together with a wireless transmitter for communicating with a user console.Filed by International Business Machines Corporation, published 2020-01-09.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120191476A1 | Systems and methods for collection, organization and display of EMS information | 307 |
| 2 | US20110288379A1 | Body sign dynamically monitoring system | 304 |
| 3 | US20110172550A1 | Uspa: systems and methods for EMS device communication interface | 251 |
| 4 | US20170303187A1 | Worker safety system | 222 |
| 5 | US20130096649A1 | Systems and methods for EMS device communication interface | 195 |
| 6 | US20110295078A1 | Systems and methods for collection, organization and display of EMS information | 171 |
| 7 | US20140075506A1 | Extensible and Scalable Distributed Computing and Communication Remote Services Platform for Telemetry Collec… | 148 |
| 8 | WO2018107129A1 | Crispr effector system based diagnostics | 146 |
| 9 | US20180361040A1 | Breast pump system | 138 |
| 10 | US9351653B1 | Multi-channel reconfigurable systems and methods for sensing biopotential signals | 136 |
Citation counts favour older records simply because they have had longer to accumulate citations inside the searched corpus — read them as a signal of influence on later filers, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-outs from the concentration, trend and citation data that matter more than the raw counts on their own.
The core claim space is already occupied
Five assignees hold nearly two-thirds of all records in scope, and the ranked ten hold 93.7%. For a new entrant, this means the foundational sensing and delivery-interface claims in electrotherapy and diagnostic wearables are likely already staked out by research institutes and established device makers.
Filing has cooled from its 2019 peak, not accelerated
Volume peaked at 136 records in 2019 and has since eased; the 2021-to-2024 window — the last stretch not distorted by publication lag — shows a clear pullback rather than continued growth. Recent-year momentum by individual leading assignees mostly reads flat or down, reinforcing the same signal.
Electrotherapy and informatics carry the claim density, not consumer wearables
The heaviest classes are electrotherapy/radiation therapy and healthcare informatics, with diagnosis-and-surgery close behind. Commerce and business-process classes like G06Q are a small fraction by comparison, suggesting most contested claim territory is clinical and data-processing, not administrative.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to wearable medical devices patent landscape, with the prior art for and against each one.
Leaders, collaboration patterns and where the field is thinning out
The ranked leaders split between academic research institutes with broad early claims and device makers with narrower, product-tied filings; several of the strongest co-filing pairs are between research institutions rather than between a research institute and a commercial partner.
A research-institute leader with the deepest single-assignee position
The top assignee holds more than double the fifth-ranked filer's count, and its strongest co-assignee pairings are with two other major research institutions rather than with an industry partner — a pattern typical of foundational biosensing and genetic-measurement work that later gets licensed downstream.
Several top-ranked filers show no filings in the latest year
More than one of the leading assignees recorded zero filings in the most recent year, a -100% year-over-year change. Given publication lag, this likely reflects filings still working through the pipeline rather than a genuine exit, but it means recent competitive signal from these names is currently thin.
US filing leads by a wide margin, EPO and PCT next
The United States receives more than double the filings of the next office, the EPO, with the PCT route close behind at 103. Australia, Germany and Canada trail well behind, indicating that protection strategy for this field is built primarily around US and European/PCT coverage rather than a wide multi-jurisdiction spread.
| Assignee | Recent year | YoY |
|---|---|---|
| Boston Scientific Neuromodulation Corp | 1 | -75% |
| The Broad Institute, Inc. | 0 | -100% |
| Massachusetts Institute of Technology | 0 | -100% |
| President & Fellows of Harvard College | 0 | -100% |
| Zoll Medical Corporation | 0 | -100% |
| Cardiac Pacemakers, Inc. | 0 | — |
| Willow Blossom Holdco Ltd | 0 | — |
| Qualcomm Inc | 0 | -100% |
Where to take this analysis
The dataset points to a field with an occupied core and a thinning edge — the next step is usually a targeted claim check rather than another broad search.
Check freedom-to-operate on a specific sub-area
Before drafting claims in tissue-interface calibration, flow-regulation feedback, or device-to-cloud interfaces, run a targeted prior-art check against the leading assignees' existing families rather than the field as a whole.
Explore in EurekaTrack the leading assignees' pipeline, not just their published counts
Several top filers show a sharp drop in the latest year that is likely a publication-lag artifact; monitoring their pending applications directly gives a clearer read on where they are actually pushing next.
Explore in EurekaMap co-filing relationships before assuming a partner is open
The strongest co-assignee pairs in this field sit between research institutions already tied together on multiple families — worth confirming exclusivity before approaching them for licensing conversations.
Explore in EurekaFrequently asked questions
The assignee ranking for this dataset is led by a research institute with 116 records, well ahead of the fifth-ranked filer at 82. The top five assignees combined hold 65.8% of all 798 records in scope, and the top ten hold 93.7%, so filing activity is heavily concentrated rather than spread evenly across the field. Several of the leading names are academic research institutions rather than device manufacturers, reflecting how much foundational sensing and diagnostic work in this space originates in university and institute labs before being licensed or commercialized.
Not currently, based on the comparable years available. Filing peaked at 136 records in 2019 and, across the 2021-to-2024 span — the most recent stretch not distorted by publication lag — volume fell 34%, from 89 to 59 records. Figures for 2025 and 2026 will rise as later-filed applications publish, since publication typically lags filing by about 18 months, so the most recent years should not yet be read as a continuation of the decline or as a rebound.
The largest IPC subclass is A61N, electrotherapy and radiation therapy, appearing in 36.7% of the 798 records, followed by G16H healthcare informatics at 26.8% and A61B diagnosis and surgery at 25.1%. Meaningful overlap also exists with genetic and enzymatic measurement classes, C12N and C12Q, each above 12%, showing that wearable sensing claims frequently intersect with molecular diagnostics rather than staying purely electronic. Because a single record can carry multiple IPC classes, these percentages add up to more than 100% of the record total.
The dense clusters sit in electrotherapy, healthcare informatics and general diagnostic sensing, all held disproportionately by the leading assignees. Comparatively thinner claim territory sits in adjacent areas such as tissue-interface calibration for chronic wear, wireless flow-regulation feedback loops, and body-worn device-to-cloud interface protocols — these appear far less often as a dedicated claim focus even though they connect directly to the heavily filed core. Any filing strategy here should still run a specific freedom-to-operate check, since low volume does not guarantee the area is unclaimed.
US20200009321A1, filed by IBM, claims a wrist-worn annular housing with a receptacle for an intravenous delivery tube, a flow regulator that modifies a geometric characteristic of that tube, and a wireless transmitter to a user console. It specifically blocks designs combining all of those elements: wrist-worn form factor, physical tube-geometry regulation, and wireless console reporting for IV monitoring. A device that monitors IV flow through a different mechanism — for example, optical or pressure-based sensing without mechanical tube deformation — or that is not wrist-mounted, would sit outside this particular claim scope, though a full clearance search against the broader dataset is still advisable.
Research Wearable Medical Devices Patent Landscape in depth with Eureka
Go past this page: query the whole wearable medical devices patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.